Brown Advisory Inc. Sells 556 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Posted by admin on Aug 14th, 2022

Brown Advisory Inc. lowered its stake in Cryoport, Inc. (NASDAQ:CYRX – Get Rating) by 10.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,740 shares of the consumer goods maker’s stock after selling 556 shares during the period. Brown Advisory Inc.’s holdings in Cryoport were worth $278,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Pinebridge Investments L.P. bought a new position in Cryoport in the fourth quarter valued at about $77,000. Commonwealth Equity Services LLC bought a new position in Cryoport in the fourth quarter valued at about $244,000. GSA Capital Partners LLP acquired a new stake in shares of Cryoport during the fourth quarter valued at about $247,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Cryoport by 49.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,937 shares of the consumer goods maker’s stock valued at $351,000 after purchasing an additional 1,959 shares in the last quarter. Finally, Ensign Peak Advisors Inc acquired a new stake in shares of Cryoport during the fourth quarter valued at about $355,000.

Cryoport Stock Up 3.2 %

Cryoport stock opened at $45.00 on Friday. The stock’s 50 day moving average is $32.90 and its 200 day moving average is $31.36. The company has a quick ratio of 13.69, a current ratio of 14.21 and a debt-to-equity ratio of 0.73. Cryoport, Inc. has a one year low of $19.82 and a one year high of $86.30.

Cryoport (NASDAQ:CYRX – Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The consumer goods maker reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.08). Cryoport had a negative net margin of 125.96% and a negative return on equity of 14.43%. The business had revenue of $64.20 million during the quarter, compared to analyst estimates of $64.58 million. During the same period last year, the firm posted ($0.16) earnings per share. Cryoport’s quarterly revenue was up 14.2% compared to the same quarter last year. On average, research analysts anticipate that Cryoport, Inc. will post -0.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CYRX has been the topic of a number of recent research reports. KeyCorp cut their price target on Cryoport from $92.00 to $52.00 in a research note on Friday, May 6th. BTIG Research cut their price target on Cryoport from $95.00 to $60.00 in a research note on Friday, May 6th. B. Riley cut their price target on Cryoport from $61.00 to $55.00 in a research note on Tuesday, May 17th. Roth Capital cut their price target on Cryoport from $90.00 to $67.00 in a research note on Tuesday, May 3rd. Finally, Needham & Company LLC lifted their price target on Cryoport from $41.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, July 12th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cryoport presently has a consensus rating of “Buy” and an average target price of $61.33.

Cryoport Profile

(Get Rating)

Cryoport, Inc, a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle.